SCHEDULE: Khosla Ventures Reduces BioAge Labs Stake Below 5%

Khosla Ventures and affiliates have filed an amendment to their Schedule 13G, reporting a decrease in beneficial ownership of BioAge Labs, Inc. to below the 5% threshold.

Summary

• Khosla Ventures VI, LP and Khosla Ventures Opportunity I, LP, along with their associated entities and Vinod Khosla, have reported a reduction in their beneficial ownership of BioAge Labs, Inc. common stock.
• The aggregate beneficial ownership is now 1,798,702 shares, representing 4.0% of the total outstanding common stock.
• This filing is a voluntary amendment to reflect that the reporting persons' ownership has fallen below the 5% reporting threshold, primarily due to changes in the issuer's total outstanding shares as reported in the May 8, 2026, Form 10-Q.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. The reduction in ownership percentage is attributed to the issuer's share count increase rather than a direct divestment of shares by the reporting persons.

Positives

• The filing confirms that the reporting entities remain invested in the company, albeit at a reduced percentage of total outstanding shares.

Negatives

• The reduction in ownership percentage below the 5% threshold may be perceived by some market participants as a decrease in long-term institutional commitment.

Risks

• Future sales of shares by major institutional investors could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding future investment intentions was provided in this filing.

Industry Context

StockSavvy.ai notes that institutional ownership shifts in biotech firms are common following capital raises or secondary offerings that dilute early-stage venture capital positions. This filing reflects a technical adjustment in ownership percentage rather than a strategic exit.

Comparison to Industry Standards

• The filing is consistent with standard regulatory requirements for venture capital firms adjusting their reporting status after dilution events.
• The 4% ownership level remains a significant position for a venture capital firm in a publicly traded biotech company.

Stakeholder Impact

• Shareholders should note the change in reporting status, though the actual number of shares held by the reporting group remains unchanged.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

BioAge Labs, Khosla Ventures, Schedule 13G, Beneficial Ownership, Vinod Khosla, Biotech